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Editorial
World Kidney Day 2011: Protect Your Kidneys, 
Save Your Heart
William G. Couser, Miguel C. Riella
March 10, 2011 marks the celebration of the sixth World 
Kidney Day (WKD), an annual event jointly sponsored 
by the International Society of Nephrology and the 
International Federation of Kidney Foundations. Since 
its inception in 2006, WKD has grown dramatically to 
become the most widely celebrated event associated with 
kidney disease in the world and the most successful 
effort to raise awareness among the general public and 
government health officials about the dangers of kidney 
disease, especially chronic kidney disease (CKD).
In 2011, WKD calls attention to the large, often unap-
preciated role played by kidney dysfunction in increas-
ing premature cardiovascular disease, the most common 
cause of morbidity and mortality worldwide [1]. Can a 
focus on early detection and prevention of kidney dis-
ease improve long-term cardiovascular health? In this 
editorial, we hope to convey the message that increased 
attention to the kidneys can indeed improve long-term 
health outcomes by reducing both kidney and cardio-
vascular disease. It should therefore be a central com-
ponent of any global health strategy intended to reduce 
the enormous and growing burden of chronic non-
communicable diseases (NCDs).
CARDIOVASCULAR DISEASE AND THE KIDNEY
Cardiovascular disease (CVD) is the most common of 
the chronic NCDs that affect global mortality rates. 
About 30% of all deaths worldwide and 10% of all 
healthy lives lost to disease are accounted for by CVD 
alone [1]. Although there has been some decline in mor-
tality from CVD in developed countries, no such decline 
has been reported in developing countries, ethnic and 
socially disadvantaged minority populations, or people 
with accompanying CKD [2,3].
The presence of CKD significantly increases the risk 
of a cardiovascular event in patients with diabetes or 
hypertension [4,5]. Less well appreciated is the fact that 
CKD alone is a strong risk factor for CVD, independent 
of diabetes, hypertension, or any other conventional risk 
factor [6,7]. This is especially true when an increase in 
proteinuria, a major target of any CKD screening pro-
gram, is present [6–9].
The 20- to 30-fold increase in CVD in patients with 
end-stage renal disease (ESRD) has long been recognized, 
but the increased risk for CVD associated with lesser 
degrees of renal functional impairment was definitively 
demonstrated only in 2004. Go et al reported a graded 
association between the glomerular filtration rate (GFR) 
and the risk of death, CV events, and hospitalizations. 
Their data were based on the findings of a community-
based study of more than 1.1 million individuals [6].
Is this dramatic increase in CVD risk really associ-
ated with CKD, or does it simply reflect the coexistent 
diabetes or hypertension that are present in most of these 
patients? The independent effect of CKD alone has now 
been well documented in many studies [7], with one 
study of a high-risk population showing that the risk of 
cardiac death is increased 46% in those with a GFR of 
60–90 mL/min and 131% in those with a GFR of 30–
60 mL/min, independent of traditional CV risk factors, 
including diabetes and hypertension [10]. The increased 
risk for CV events and mortality in people > 55 years of 
age with CKD alone is equivalent to, or even higher than, 
that seen in patients with diabetes or previous myocar-
dial infarction [11]. Both general [6,12] and high-risk 
[13,14] populations exhibit an increased risk of CVD 
with CKD. The increased risk for CVD is not confined to 
the elderly: Among volunteers with an average age of 
45 years, the risk for myocardial infarction, stroke, and 
all-cause mortality was doubled in those with CKD [14].
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PROTEINURIA AND CARDIOVASCULAR RISK
When considering the value of recommending screening 
for CKD along with conventional CVD risk factors in 
selected individuals, data show that the risk of CVD is 
better correlated with proteinuria (albuminuria) than with 
GFR alone. This is particularly relevant because protein-
uria is virtually always a marker of kidney disease and 
is not a conventional CVD risk factor [6,8,9,15].
With regard to proteinuria as a predictor of late CVD, 
the Prevention of Renal and Vascular End-Stage Disease 
(PREVEND) study showed a direct linear relation be-
tween albuminuria and a risk of CV death in the general 
population, even at levels of albumin excretion generally 
considered within the normal range (15–29 mg/day). The 
risk increased more than 6-fold when albumin excretion 
exceeded 300 mg/day [8].
Recent data from the U.S. National Health and Nu-
trition Examination Survey (NHANES) database and 
from Japan have documented an independent effect of 
albuminuria on the risk of both CVD and all-cause mor-
tality at all levels of the GFR [15,16]. In patients with 
congestive heart failure but without diabetes, hyperten-
sion and increased urinary albumin predicts both CV 
and all-cause mortality, independent of a reduced GFR 
[17]. Similar results have been obtained from patients 
with coronary disease or previous myocardial infarction: 
Proteinuria conferred a greater risk of mortality than 
reduced GFR in those patients, although both adversely 
affected outcome [18].
It is of interest that not only the likelihood, but also 
the time to development of a CV event, is accelerated 
significantly by the presence of proteinuria at all levels 
of GFR [19]. Among nondiabetic subjects with normal 
serum creatinine levels undergoing percutaneous coro-
nary interventions, about 78% had demonstrable CKD 
when screened more stringently for the estimated GFR 
and urinary protein [20]. Not only was the presence 
of CKD a likely factor in accelerating development of 
coronary disease in these patients, it has been associated 
with an increase in other risks, including hemorrhagic 
complications, contrast nephropathy, restenosis, and 
death [10]. Thus, multiple studies now confirm that 
proteinuria is a graded risk factor for CVD independent 
of the GFR, hypertension, or diabetes. This risk also 
extends into ranges of albumin excretion generally 
considered “normal” [21,22]. Increased CV risk has 
been well demonstrated in several studies where only 
dipsticks were used to screen for increased protein ex-
cretion [6,18,23]. Although there has been concern that 
CKD diagnosed by reduced GFR alone identifies pre-
dominantly older adults at increased risk because of 
age alone [24], the connection between proteinuria as 
an independent risk factor for CV-related mortality 
has been confirmed by meta-analysis of 22 general 
population cohort studies and in both old (> 65 years) 
and younger people of several nationalities and racial 
groups [23].
CAN TREATMENT OF CHRONIC KIDNEY DISEASE 
REDUCE CARDIOVASCULAR DISEASE?
Finally, and most importantly from a clinical perspec-
tive, provocative data suggest that renal-targeted inter-
ventions designed to reduce proteinuria and slow the 
progression of CKD can reduce CVD risk as well. 
Angiotensin-converting enzyme (ACE) inhibitors and/
or angiotensin II receptor blockers are of documented 
benefit in slowing progression of established diabetic 
and nondiabetic CKD [25–29].
In regard to slowing progression, the incidence of 
CVD in CKD is significantly higher when there is a rapid 
decrease in the GFR independent of other risk factors, 
suggesting that interventions that slow progression may 
also reduce CVD [19]. The PREVEND study reported 
a 40% (although not significant) reduction in CV events 
over 4 years in patients screened from a general popula-
tion with no risk factors except increased urinary albu-
min who were treated with ACE inhibitors [30]. In this 
pilot study, the effect was most notable in people with 
albumin excretion rates of > 50 mg/day. A post hoc cost-
effectiveness analysis noted that the intervention is 
likely cost-effective in that population [31]. In the REN-
NAL study, CV endpoints were significantly reduced 
in direct proportion to the reduction of albuminuria with 
ACE inhibitor therapy in patients with type 2 diabetes, 
and albuminuria proved to be the only predictor of CV 
outcome [32].
The potential benefit of renal-targeted therapies has 
recently been highlighted by observations that doses of 
renin-angiotensin system (RAS) blockers higher than 
those required for blood pressure control can further re-
duce proteinuria independent of effects on blood pressure 
or the GFR. Also, addition of salt restriction or diuretics, 
both inexpensive interventions, can further enhance the 
proteinuria-reducing effect of RAS blockade [33,34].
Data are not yet available to establish that screening 
for CKD and subsequent interventions do indeed reduce 
CV mortality and are cost-effective in young people 
(< 55 years) [35]. However, it is known that albuminuria 
is a better predictor of renal and cardiovascular events 
than blood pressure alone, that reducing proteinuria is 
more renal and cardioprotective than lowering blood pres-
sure alone, and that identification of CKD can improve 
CV outcomes.
CONCLUSION
As celebrations of the sixth World Kidney Day approach 
on March 10, 2011, it is worth noting that prior to the 
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past decade kidney disease was seen by most govern-
ment and public health authorities as largely confined 
to patients with ESRD. It is fortunate that ESRD is a 
rare condition, because the enormous cost of renal re-
placement therapy can disproportionately consume scarce 
health care resources and is well beyond the means of 
countries inhabited by more than 80% of the world’s 
population [36,37].
Much has changed. We now appreciate that kidney 
disease is not rare—some 10% of the population has 
evidence of renal dysfunction. We know that these in-
dividuals are not of concern simply because a few 
progress to ESRD, but more because they carry a greatly 
enhanced risk of premature death from CVD, the single 
largest and most expensive health care threat we confront 
at a global level [1]. Just as progress is being made in 
addressing most of the traditional CV risk factors, CKD 
has emerged as yet another one that causes substantial 
vascular toxicity independently.
Fortunately, there is good news. Biomarkers of CKD 
(proteinuria, estimated GFR) are easy and relatively 
inexpensive to detect, and proteinuria emerges early in 
the evolution of generalized vascular disease. Kidney-
targeted detection and prevention programs offer a valu-
able opportunity to institute early preventive measures 
that go beyond traditional cardioprotective approaches. 
There is now compelling evidence that including selec-
tive screening for CKD in global health programs de-
signed primarily to reduce CVD can significantly improve 
the outcomes of not only renal disease, but especially 
NCDs such as diabetes and CVD, which dominate future 
health care strategies. Roadmaps for accomplishing this 
have already been presented in both developed [38,39] 
and emerging [1] countries.
Effective implementation of such strategies will 
come only when both the general public and the renal 
community work together to convince health authorities 
that it is in the public interest to do so. It is our sincere 
hope that the worldwide celebration of World Kidney 
Day 2011 will provide an opportunity to reinforce the 
message that kidney disease is indeed common, harm-
ful, and treatable, and that protecting the kidneys is an 
important health strategy that may save one’s heart.
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